As of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc. Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.

Oyster Point Pharma, Inc.

Viatris is a global healthcare company that produces high-quality medicines across a range of therapeutic areas, including both noncommunicable and infectious diseases.

Viatris

Pharmaceutical Manufacturing

Oyster Point Pharma | 11,747 followers on LinkedIn. Commercial-stage biopharmaceutical company focused on pharmaceutical therapies to treat ophthalmic diseases. | Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.

Kelly R.

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21
net income	-6.60M -	-16.50M 150.01%	-45.71M 176.99%	-70.52M 54.27%	-100.66M 42.74%
depreciation and amortization			19K -	461K 2,326.32%	141K 69.41%
deferred income tax
stock based compensation	119K -	154K 29.41%	3.27M 2,020.78%	6.97M 113.50%	11.95M 71.35%
change in working capital	846K -	-734K 186.76%	1.61M 319.48%	4.69M 190.94%	-3.03M 164.69%
accounts receivables					-6.66M -
inventory					-6.96M -
accounts payables	61K -	44K 27.87%	38K 13.64%	1.77M 4,565.79%	3.87M 118.16%
other working capital	785K -	-778K 199.11%	1.57M 302.19%	2.91M 85.25%	6.72M 130.65%
other non cash items	962K -				2.23M -
net cash provided by operating activities	-4.67M -	-17.08M 265.49%	-40.81M 138.92%	-58.40M 43.08%	-89.37M 53.03%
investments in property plant and equipment			-200K -	-700K 250%	-1.49M 112.14%
acquisitions net
purchases of investments
sales maturities of investments
other investing activites
net cash used for investing activites			-200K -	-700K 250%	-1.49M 112.14%
debt repayment
common stock issued			82.13M -	112.91M 37.47%
common stock repurchased
dividends paid
other financing activites	26.18M -		92.85M -	-361K 100.39%	91.64M 25,485.60%
net cash used provided by financing activities	26.18M -		174.99M -	112.55M 35.68%	91.64M 18.57%
effect of forex changes on cash
net change in cash	21.50M -	-17.08M 179.45%	133.97M 884.23%	53.45M 60.10%	787K 98.53%
cash at beginning of period	810K -	22.31M 2,654.44%	5.23M 76.57%	139.20M 2,562.55%	192.65M 38.40%
cash at end of period	22.31M -	5.23M 76.57%	139.20M 2,562.55%	192.65M 38.40%	193.43M 0.41%
operating cash flow	-4.67M -	-17.08M 265.49%	-40.81M 138.92%	-58.40M 43.08%	-89.37M 53.03%
capital expenditure			-200K -	-700K 250%	-1.49M 112.14%
free cash flow	-4.67M -	-17.08M 265.49%	-41.02M 140.09%	-59.10M 44.09%	-90.86M 53.73%

COM:OYSTERPOINTRX

Viatris

Last Close

11.17

30/12 21:00

Volume Today

2.09M

Avg: -

Preview